教学人员

何永乐教授

助理教授

PhD in Neuroscience (HKU), FIBMS(UK), MRSB (UK)

ST506
+852 3400 8966
philip-wl.ho@polyu.edu.hk

ORCID ID

SCOPUS ID

Google Scholar

简历

何永乐教授分别于1997年和1999年在香港科技大学获得生物化学学士和哲学硕士学位。并于2004年在香港大学内科学系获得博士学位。在加入香港理工大学之前，何教授曾在香港大学担任博士后，研究助理教授和科学主任。

何教授的临床前研究重点是主要围绕柏金逊症及其相关的多种神经系统疾病，包括使用体外和体内实验模型阐明与LRRK2突变相关的线粒体功能障碍和自噬受损的致病机制，以开发新的神经保护策略。除了自主研发的LRRK2突变小鼠模型外，他还开始製备柏金逊症患者来源的诱导多能干细胞作为疾病替代模型。此外，何教授还作为项目负责人与海洋污染国家重点实验室（SKLMP，CityU）合作研究新兴化学品（CECs）的环境风险。2015年他开发了一种新型的基于人类细胞的检测试剂盒，用于评估环境异雌激素和各种内分泌干扰化合物诱导的雌激素效应。这种新型检测採用了一种自主研发的蛋白标记作为试剂盒的主要检测成分。这项发明已在美国、欧洲和中国获得了专利。

何教授在著名国际期刊中发表了50多篇研究论文和邀请评论，包括《Autophagy》, 《npj Parkinson’s disease》, 《Translational Neurodegeneration》等。何教授作为PI / Co-I获得了HMRF和RGC / GRF的多项科研资助，并负责指导神经科学硕士和博士研究生的学习和实验室工作。此外，何教授还积极参与研究社区服务，被邀请担任一些著名期刊的编委、编委会成员和审稿人，包括《Nature Communications》、《Translational Neurodegeneration》、《Journal of Neurology》、《Brain and Behavior》以及《Frontiers in Molecular Neuroscience》。

学历

Doctor of Philosophy (PhD): Dept of Medicine, The University of Hong Kong
Master of Philosophy (MPhil) in Biochemistry, The Hong Kong University of Science and Technology
Bachelor of Science (BSc) in Biochemistry, The Hong Kong University of Science and Technology

专业资格

Fellow - Institute of Biomedical Science, United Kingdom (since Jan 2021)
Professional member (Explorer) - Society of Environmental Toxicology and Chemistry (SETAC Asia-Pacific) - a global, non-profit professional organization dedicated to the advancement of environmental science and management (since Jun 2024)
Member – Society for Neuroscience (SfN), USA (since Nov 2025)
Member – The Royal Society of Biology, United Kingdom (since Jan 2026)
Full member – State Key Laboratory of Marine Environmental Health (SKLMEH), City University of Hong Kong, Hong Kong (since Oct 2022)
Principal Investigator - Research Centre for Chinese Medicine Innovation (RCMI), The Hong Kong Polytechnic University, Hong Kong SAR, China (since May 2025)
Principal Investigator - Mental Health Research Centre, PolyU Academy for Interdisciplinary Research, The Hong Kong Polytechnic University, Hong Kong SAR, China (since Jan 2024)
Principal Investigator - Research Institute for Smart Ageing, The Hong Kong Polytechnic University, Hong Kong SAR, China (since Apr 2024)

研究兴趣

Choi ZYK, Liu HF, Chang EES, Pang SYY, Luo LY, Ruan Y, Wang Q, Malki Y, Zhang SXY, Weng KY, Lau BWM, Ng RCL, Zhang Z, Ho SL, Ho PWL*. Long-term oral glucocerebrosidase activator reduces soluble α-synuclein oligomer accumulation in parkinsonian LRRK2 mutant mouse brain npj Parkinsons disease. 2025; 11:359 doi.org/10.1038/s41531-025-01205-7.
Tang W, Chen B, Ho PWL, Zheng Q, Nga CTY, Zhu Z, Leung GKK*, and Kiang KM*. Activation of chaperone-mediated autophagy suppresses glioblastoma by promoting wild-type IDH1/isocitrate dehydrogenase 1 (IDH1) degradation. Autophagy 2025; 30:1-21. doi.org/10.1080/15548627.2025.2589906.
Ng MHF, Lam JWY, Choi ZYK, Liu H, Ho PWL, Lau BWM and Yee BK*. Affective Phenotypes in Heterozygous LRRK2 R1441G Knock-In mice. Frontiers in Genetics. 2025; 16:1629897. doi: 10.3389/fgene.2025.1629897.
Kwok JYY*, Chan LML, Lai CA, Ho PWL, Choi ZYK, Auyeung M, Pang SYY, Choi EPH, Fong DYT, Yu DSF, Lin CC, Walker R, Wong SY, Ho RTH. Effects of meditation and yoga on anxiety, depression and chronic inflammation in patients with Parkinson's disease: A randomised clinical trial. Psychotherapy and Psychosomatics. 2025; 94(2):101-118. doi: 10.1159/000543457.
Chang EES, Liu HF, Choi ZYK, Malki Y, Zhang SXY, Pang SYY, Kung MHW, Ramsden DB, Ho SL, Ho PWL*. Loss of mitochondrial Ca2+ response and CaMKII/ERK activation by LRRK2R1441G mutation correlated with impaired depolarization-induced mitophagy. Cell Communication and Signaling. 2024; 22:485. doi.org/10.1186/s12964-024-01844-y.
Kwok JYY*, Auyeung M, Pang SYY, Ho PWL, Yu DSF, Fong DYT, Lin CC, Walker R, Wong SY, Ho RTH. A randomized controlled trial on the effects and acceptability of individual mindfulness techniques - meditation and yoga - on anxiety and depression in people with Parkinson's disease: a study protocol. BMC Complement Med Ther. 2023; 23(1):241. doi: 10.1186/s12906-023-04049-x.
PWL Ho*, LF Li, HF Liu, ZYK Choi, EES Chang, SYY Pang, Y Malki, CT Leung, MHW Kung, DB. Ramsden, SL Ho*. In vivo overexpression of synaptogyrin-3 (SYNGR3) promotes striatal synaptic dopamine uptake in LRRK2R1441G mutant mouse model of Parkinson’s disease. Brain and Behavior. 2023; 13:e2886. doi:10.1002/brb3.2886.
PWL Ho*#, EES Chang#, CT Leung, HF Liu, Y Malki, SYY Pang, ZYK Choi, Y Liang, WS Lai, Y Ruan, KMY Leung, S Yung, JCW Mak, MHW Kung, DB. Ramsden, SL Ho*. Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain α-synuclein oligomers without adverse effects. npj Parkinsons disease. 2022; 8:115. doi:10.1038/s41531-022-00386-9.
Li L#, Ho PWL#, Liu HF, Pang SYY, Chang EES, Choi ZYK, Malki Y, MHW Kung, Ramsden DB, Ho SL*. Transcriptional Regulation of the Synaptic Vesicle Protein Synaptogyrin-3 (SYNGR3) Gene: The Effects of NURR1 on Its Expression. International Journal of Molecular Sciences 2022; 23(7):3646. doi:10.3390/ijms23073646.
Chang EES, Ho PWL*, Liu HF, Pang SYY, Leung CT, Malki Y, Choi ZYK, Ramsden DB, Ho SL*. LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease. Translational Neurodegeneration 2022; 11:10. https://doi.org/10.1186/s40035-022-00285-2.
Pang SYY, Lo RCN, Ho PWL, Liu HF, Chang EES, Leung CT, Malki Y, Choi ZYK, Wong WY, Kung MHW, Ramsden DB, Ho SL*. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease. Translational Neurodegeneration 2022; 11:5. doi:10.1186/s40035-022-00281-6.
Klinosky DJ*, … Ho PWL, Ho SL, Leung CT, Liu HF, Pang SY, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy 2021; 17(1):1-382. (doi:10.1080/15548627.2020.1797280).
Liu HF#, Ho PWL#, Leung CT, Pang SY, Chang EES, Choi ZYK, Kung MHW, Ramsden DB, Ho SL*. Aberrant mitochondrial morphology and function associated with impaired mitophagy and DNM1L/ERK signaling are found in aged mutant Parkinsonian LRRK2R1441G mice. Autophagy 2021; 17(10):3196-3220. (doi: 10.1080/15548627.2020.1850008).
Ho SL*, Ho PWL, Siu DCW. Parkinson disease and leucine-rich repeat kinase 2 gene mutation: abridged secondary publication. Hong Kong Med J 2020; 26(Suppl 8): S22-6.
Ho PWL, Leung GC, Liu HF, Pang SY, Lam CS, Xian JW, Li LF, Kung MHW, Ramsden DB, Ho SL*. Age-dependent accumulation of oligomeric a-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA). Autophagy 2020; 16(2):347-370. (doi: 10.1080/15548627.2019.1603545).
Pang SY, Ho PWL, Liu HF, Leung GC Li LF, Chang EES, Ramsden DB, Ho SL*. The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease. Translational Neurodegeneration 2019; 8:23. (doi:10.1186/s40035-019-0165-9).

Human Catechol-O-methyltransferase (COMT) Assay [European Patent Office (EPO): EP2328909A1] - Listed inventor
Human Catechol-O-methyltransferase (COMT) Assay [United State Patent & Trademark Office (USPTO): US20100081147A1] - Listed inventor
Human Catechol-O-methyltransferase (COMT) Assay [China Cooperation Treaty (PCT): CN102203119A] - Listed inventor